Covered recipient · General Payments record
SHILPA BADAL RAVAL
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2024
$431.96
- Reported across 10 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $431.96 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $141.57 | 1 |
| Acerta Pharma LLC | $121.28 | 1 |
| Novo Nordisk AS | $102.41 | 4 |
| Amgen Inc. | $35.41 | 2 |
| Lilly USA, LLC | $31.29 | 2 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2024 | $431.96 | 10 |
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $141.57 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078887863 | CMS |
| Amgen Inc. | $13.32 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116045886 | CMS |
| Amgen Inc. | $22.09 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117663081 | CMS |
| AstraZeneca Pharmaceuticals LP | $121.28 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104766182 | CMS |
| Lilly USA, LLC | $14.04 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135376598 | CMS |
| Lilly USA, LLC | $17.25 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135427488 | CMS |
| Novo Nordisk Inc | $29.85 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097533043 | CMS |
| Novo Nordisk Inc | $31.84 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097730701 | CMS |
| Novo Nordisk Inc | $15.72 | 12/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097510384 | CMS |
| Novo Nordisk Inc | $25.00 | 12/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096690605 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2024
- Source files
- Dataset page · Bulk file · PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.